Inhibition of reverse transcriptase activity increases stability of the HIV-1 core

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 683-687

  Yang, Yang ^a   Fricke, Thomas ^a   Diaz Griffero, Felipe ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TRIPARTITE MOTIF PROTEIN 5;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION; VIRUS CORE; VIRUS MUTATION; VIRUS PARTICLE; VIRUS TRANSCRIPTION;

ANIMALS; CELL LINE; DOGS; HIV REVERSE TRANSCRIPTASE; HIV-1; REVERSE TRANSCRIPTION; VIRUS INTEGRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871985539     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01228-12     Document Type: Article

References (29)

1. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, Vogt VM, Johnson MC. 2004. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11:672-675.
2. Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD. 2003. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22: 1707-1715.
3. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677.
4. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ. 2002. Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol. 159:441-452.
5. Warrilow D, Meredith L, Davis A, Burrell C, Li P, Harrich D. 2008. Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro. J. Virol. 82:1425-1437.
6. Warren K, Warrilow D, Meredith L, Harrich D. 2009. Reverse transcriptase and cellular factors: regulators of HIV-1 reverse transcription. Viruses 1:873-894.
7. Warrilow D, Warren K, Harrich D. 2010. Strand transfer and elongation of HIV-1 reverse transcription is facilitated by cell factors in vitro. PLoS One 5:e13229. doi:10.1371/journal.pone.0013229.
8. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J. 2007. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 369:400-410.
9. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, Sodroski J. 2007. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J. Virol. 81:2138-2148.
10. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz- Griffero F, Anderson DJ, Sundquist WI, Sodroski J. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103:5514-5519.
11. Ohagen A, Gabuzda D. 2000. Role of Vif in stability of the human immunodeficiency virus type 1 core. J. Virol. 74:11055-11066.
12. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, Watanabe S, Kigawa T, Yokoyama S, Aiken C, Diaz-Griffero F. 2011. RING domain mutations uncouple TRIM5alpha restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J. Virol. 86:1717-1727.
13. Diaz-Griffero F, Perron M, McGee-Estrada K, Hanna R, Maillard PV, Trono D, Sodroski J. 2008. A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 378:233-242.
14. Arfi V, Lienard J, Nguyen XN, Berger G, Rigal D, Darlix JL, Cimarelli A. 2009. Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection. J. Virol. 83:7524 -7535.
15. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, Darlix JL, Cimarelli A. 2011. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 7:e1002221. doi:10.1371/journal.ppat.1002221.
16. Hulme AE, Perez O, Hope TJ. 2011. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 108:9975-9980.
17. Berube J, Bouchard A, Berthoux L. 2007. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells. Retrovirology 4:68. doi: 10.1186/1742-4690-4-68.
18. Ohkura S, Goldstone DC, Yap MW, Holden-Dye K, Taylor IA, Stoye JP. 2011. Novel escape mutants suggest an extensive TRIM5alpha binding site spanning the entire outer surface of the murine leukemia virus capsid protein. PLoS Pathog. 7:e1002011. doi:10.1371/journal.ppat.1002011.
19. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. 2011. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85:542-549.
20. D'Andrea G, Brisdelli F, Bozzi A. 2008. AZT: an old drug with new perspectives. Curr. Clin. Pharmacol. 3:20 -37.
21. Mulky A, Sarafianos SG, Arnold E, Wu X, Kappes JC. 2004. Subunitspecific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. J. Virol. 78:7089-7096.
22. Bukrinskaya AG. 2004. HIV-1 assembly and maturation. Arch. Virol. 149:1067-1082.
23. Fassati A, Goff SP. 2001. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 75:3626-3635.
24. Warrilow D, Harrich D. 2007. HIV-1 replication from after cell entry to the nuclear periphery. Curr. HIV Res. 5:293-299.
25. Warrilow D, Tachedjian G, Harrich D. 2009. Maturation of the HIV reverse transcription complex: putting the jigsaw together. Rev. Med. Virol. 19:324-337.
26. Yang R, Shi J, Byeon IJ, Ahn J, Sheehan JH, Meiler J, Gronenborn AM, Aiken C. 2012. Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology 9:30. doi:10.1186/1742-4690-9-30.
27. Besnier C, Takeuchi Y, Towers G. 2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U. S. A. 99:11920-11925.
28. Bothner B, Dong XF, Bibbs L, Johnson JE, Siuzdak G. 1998. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 273:673-676.
29. Hilmer JK, Zlotnick A, Bothner B. 2008. Conformational equilibria and rates of localized motion within hepatitis B virus capsids. J. Mol. Biol. 375:581-594.